Alumis Inc. Common Stock
NASDAQ:ALMSBiotechnology
+$0.21 today
- Market cap
- $568.87M
- Beta
- -0.54
- P/E (TTM)
- -12.2
- EPS (TTM)
- -$1.90
Volume 2.01M
Average 1.31M
ALMS Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
Alumis Inc. Common StockNASDAQ: ALMS
Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026
Weighted avg shares (diluted) grows, but more slowly than its trailing trend
Q2 FY2026 weighted avg shares (diluted) of 127.69M shares rose 66.6% year over year, behind the +93.6% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 2.1% from the prior quarter. Over 3 fiscal years it compounded at +384.0% a year.
Context
- Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +66.6% toward the trailing-twelve-month pace of +93.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 850.3M USD
- Year-over-year change
- +2900.1%
- 3-year CAGR
- +384.0%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 850.3M | +2900.1% |
| FY2024 | 2024-12-31 | 28.34M | -45.3% |
| FY2023 | 2023-12-31 | 51.84M | +591.5% |
| FY2022 | 2022-12-31 | 7.5M | — |
Weighted Avg Shares (Diluted) vs competitors
How ALMS compares with its peers on the latest reported figures
- ALMS's LTM Jun 2026 weighted avg shares (diluted) of 115.39M shares is the 2nd highest of the 10 companies compared; the peer median is 36.24M shares.
- Its year-over-year change of +93.6% is the highest of 10, against a peer median of +6.3%.
- Over three fiscal years its annual growth of +384.0% compares with a peer median of +8.4%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 124.17M | +37.8% | +23.4% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | 115.39M | +93.6% | +384.0% |
| LTM Mar 2026 | 68.86M | +14.8% | +15.0% | |
| LTM Mar 2026 | 60.16M | +1.0% | +0.9% | |
| FY2025 | 59.14M | +10.9% | +5.2% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | FY2024 | 36.24M | +0.0% | — |
| LTM Mar 2026 | 29.47M | +0.4% | +3.6% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | 24.5M | +1.8% | +11.6% |
| LTM Mar 2026 | 18.96M | +6.3% | +3.0% | |
| LTM Mar 2026 | 15.86M | +60.9% | +599.3% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — |
| Peer median (excluding ALMS) | 36.24M | +6.3% | +8.4% | |
Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 24.05M |
| Cost of Revenue | 250K | 0 | 3.15M | 3.5M |
| Gross Profit | (250K) | 0 | (3.15M) | 20.55M |
| Gross Margin | — | — | — | 85.5% |
| Research & Development | 101.05M | 137.68M | 265.55M | 386M |
| Selling, General & Admin | 12.55M | 20.5M | 35.2M | 91.86M |
| Operating Expenses | 113.6M | 158.17M | 297.6M | 447.76M |
| Depreciation & Amortization | 250K | 1.28M | 3.15M | 3.5M |
| EBITDA | (111.68M) | (153.71M) | (291.08M) | (248.39M) |
| EBITDA Margin | — | — | — | -1032.8% |
| Operating Income | (113.85M) | (158.17M) | (300.75M) | (427.2M) |
| Operating Margin | — | — | — | -1776.3% |
| Interest Income | 1.99M | 3.37M | 12.02M | 14.18M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 1.92M | 3.18M | 6.52M | 175.32M |
| Income Before Tax | (111.93M) | (154.99M) | (294.23M) | (251.89M) |
| Pre-Tax Margin | — | — | — | -1047.3% |
| Income Tax Expense | 0 | 0 | 0 | (8.56M) |
| Net Income | (111.93M) | (154.99M) | (294.23M) | (243.33M) |
| Net Margin | — | — | — | -1011.7% |
| EPS (Basic) | (14.93) | (2.99) | (10.38) | (2.32) |
| EPS (Diluted) | (14.93) | (2.99) | (10.38) | (2.32) |
| Weighted Avg Shares | 7.5M | 51.84M | 28.34M | 850.3M |
| Weighted Avg Shares (Diluted) | 7.5M | 51.84M | 28.34M | 850.3M |
Alumis Inc. Common Stock
NASDAQ:ALMS
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.